RP
Rivus Pharmaceuticals at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Rivus Pharmaceuticals brings 3 presentations to ObesityWeek 2026 in National Harbor. Its program centres on RV-8451, a preclinical GLP-1 receptor compound aimed at fat-specific weight loss that spares muscle. It covers mouse studies in which RV-8451 outperforms orforglipron and reverses the muscle loss that orforglipron causes.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
RP Rivus Pharmaceuticals Charlottesville, VA | |
Develops obesity and metabolic drugs aimed at fat loss while preserving muscle, including a preclinical GLP-1 receptor agonist. | Poster Sat Nov 14 7:30pm–8:30pm RV-8451, a Pre-Clinical, Muscle-Preserving GLP-1R NPA, Outperforms Orforglipron in Obesity Models Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sun Nov 15 2:30pm–3:30pm Rescuing Lean Mass: GLP-1R NPA RV-8451 Reverses Orforglipron-Induced Muscle Loss in DIO Mouse Model Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Beyond Caloric Restriction: RV-8451 GLP-1R NPA Drives Fat-Specific Weight Loss in a DIO Mouse Model Interventional and clinical studies |
Find decision makers at Rivus Pharmaceuticals
Tell us what you sell and we’ll find the people at Rivus Pharmaceuticals most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction